Regulatory Filings • Mar 30, 2020
Regulatory Filings
Open in ViewerOpens in native device viewer
BERGENBIO TO PRESENT AT THE UPCOMING 2020 SOLEBURY TROUT VIRTUAL INVESTOR CONFERENCE
Bergen, Norway, March 30, 2020 - BerGenBio, a clinical-stage biopharmaceutical
company developing novel, selective AXL kinase inhibitors for multiple cancer
indications, announces today that Richard Godfrey, Chief Executive Officer, will
present at the upcoming Solebury Trout Virtual Investor Conference. The 25
minute presentation includes an interactive Q&A with participants prompted to
submit questions electronically. Details are as follows:
Date/Time: Tuesday March 31, at 11am EDT
Access:
https://78449.themediaframe.com/dataconf/productusers/solebury/mediaframe/36522/i
ndexl.html
Webcast archive: 24 hours following the presentation an archive copy of the
presentation will be available on the Company's website at
https://www.bergenbio.com/ in section: Investors/Presentations.
About BerGenBio
BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company's proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad Phase II oncology clinical development
programme focused on combination and single agent therapy in lung cancer and
leukaemia. A first-in-class functional blocking anti-AXL antibody, tilvestamab,
is undergoing Phase I clinical testing. In parallel, BerGenBio is developing
companion diagnostic tests to identify those patient populations most likely to
benefit from bemcentinib: this is expected to facilitate more efficient
registration trials supporting a precision medicine-based commercialisation
strategy. BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK.
The company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit www.bergenbio.com
Contacts
Richard Godfrey CEO, BerGenBio ASA
+47 917 86 304
Rune Skeie, CFO, BerGenBio ASA
+47 917 86 513
International Media Relations
Mary-Jane Elliot, Chris Welsh, Lucy Featherstone, Carina Jurs
Consilium Strategic Communications
+44 20 3709 5700
Media Relations in Norway
Jan Petter Stiff, Crux Advisers
+47 995 13 891
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.